Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 30;91(1):89–98. doi: 10.1159/000530431

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Author(s). Published by S. Karger AG, Basel

This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

PMC Copyright notice

Fig. 4. — Flow cytometry evaluation of the diagnostic sample (top panel), 3 months post induction therapy (mid-panel) and 10 months post induction therapy (lower panel) in a patient with ML-DS who achieved and maintained complete remission after induction. The diagnostic sample (top panel, a) shows the presence of myeloid blasts with expression of CD7 and CD56 with the absence of HLA-DR. The post-therapy samples (mid-panel b, lower panel, c) show similar findings with persistent CD56, absent CD7, and variable HLA-DR. Aberrant CD56 expression (as indicated by the arrow) is an inherent characteristic of many DS patients and is not, in isolation, diagnostic of residual myeloid leukemia.